Pharmacokinetic and pharmacodynamic profile of ceftobiprole

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 1, 2008, Pages 96-102

  Lodise, Thomas P ^a,b   Patel, Nimish ^a   Renaud Mutart, Amy ^a   Gorodecky, Evgeny ^a   Fritsche, Thomas R ^c   Jones, Ronald N ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c JMI LABORATORIES   (United States)

Author keywords

Ceftobiprole; Cephalosporin; Gram negative; Gram positive; Monte Carlo simulation; MRSA; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; LEVOFLOXACIN; OXACILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; DOSE KIDNEY FUNCTION RELATION; DRUG ELIMINATION; DRUG PROTEIN BINDING; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; POPULATION MODEL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VOLUNTEER;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CROSS INFECTION; HUMANS; MONTE CARLO METHOD; PNEUMONIA; SKIN DISEASES, BACTERIAL;

EID: 41949087988     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.02.013     Document Type: Article

References (34)

1. Andes D., and Craig W. In-vivo pharmacodynamics of RO 63-9141 against multiple bacterial pathogens. Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON (2000)
2. Appelbaum P.C. MRSA-the tip of the iceberg. Clin. Microbiol. Infect. 12 Suppl 2 (2006) 3-10
3. Arias C.A., Singh K.V., Panesso D., and Murray B.E. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J. Antimicrob. Chemother. 60 (2007) 594-598
4. Arias C.A., Singh K.V., Panesso D., and Murray B.E. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamase-producing and vancomycin-resistant isolates. Antimicrob. Agents Chemother. 51 (2007) 2043-2047
5. Azoulay-Dupuis E., Bedos J.P., Mohler J., Schmitt-Hoffmann A., Schleimer M., and Shapiro S. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48 (2004) 1105-1111
6. Bogdanovich T., Ednie L.M., Shapiro S., and Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49 (2005) 4210-4219
7. Bogdanovich T., Clark C., Ednie L., Lin G., Smith K., Shapiro S., and Appelbaum P.C. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50 (2006) 2050-2057
8. Chambers H.F. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49 (2005) 884-888
9. Chambers H.F. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. 12 Suppl 2 (2006) 17-22
10. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26 (1998) 1-10 (quiz 11-12)
11. Davies T.A., Shang W., and Bush K. Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob. Agents Chemother. 50 (2006) 2530-2532
12. Davies T.A., Page M.G., Shang W., Andrew T., Kania M., and Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51 (2007) 2621-2624
13. Deshpande L.M., and Jones R.N. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9 (2003) 1120-1124
14. Deshpande L., Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50 (2004) 73-75
15. Entenza J.M., Hohl P., Heinze-Krauss I., Glauser M.P., and Moreillon P. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46 (2002) 171-177
16. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., and Fernandez H.T. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob. Agents Chemother. 50 (2006) 3959-3962
17. Graham D.R., Talan D.A., Nichols R.L., Lucasti C., Corrado M., Morgan N., and Fowler C.L. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin. Infect. Dis. 35 (2002) 381-389
18. Hebeisen P., Heinze-Krauss I., Angehrn P., Hohl P., Page M.G., and Then R.L. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45 (2001) 825-836
19. Jones M.E. In-vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 13 Suppl 2 (2007) 17-24
20. Jones R.N. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119 (2001) 397S-404S
21. Jones R.N., Deshpande L.M., Mutnick A.H., and Biedenbach D.J. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50 (2002) 915-932
22. Kosowska K., Hoellman D.B., Lin G., Clark C., Credito K., McGhee P., Dewasse B., Bozdogan B., Shapiro S., and Appelbaum P.C. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49 (2005) 1932-1942
23. Lepper M.H., Dowling H.F., Jackson G.G., and Hirsch M.M. Epidemiology of penicillin- and aureomycin-resistant staphylococci in a hospital population. AMA Arch. Inter. Med. 92 (1953) 40-50
24. Lin G., and Appelbaum P.C. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis. Diagn. Microbiol. Infect. Dis. 60 (2007) 233-235
25. Lodise Jr. T.P., Pypstra R., Kahn J.B., Murthy B.P., Kimko H.C., Bush K., Noel G.J., and Drusano G.L. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob. Agents Chemother. 51 (2007) 2378-2387
26. Murthy B., and Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin. Pharmacokinet. 47 (2008) 21-33
27. Pankuch G.A., and Appelbaum P.C. Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms. Antimicrob. Agents Chemother. 50 (2006) 3956-3958
28. Queenan A.M., Shang W., Kania M., Page M.G., and Bush K. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 51 (2007) 3089-3095
29. Rouse M.S., Hein M.M., Anguita-Alonso P., Steckelberg J.M., and Patel R. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. 55 (2006) 333-336
30. Schmitt-Hoffmann A., Nyman L., Roos B., Schleimer M., Sauer J., Nashed N., Brown T., Man A., and Weidekamm E. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48 (2004) 2576-2580
31. Schmitt-Hoffmann A., Roos B., Schleimer M., Sauer J., Man A., Nashed N., Brown T., Perez A., Weidekamm E., and Kovacs P. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48 (2004) 2570-2575
32. Vaudaux P., Gjinovci A., Bento M., Li D., Schrenzel J., and Lew D.P. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49 (2005) 3789-3793
33. West M., Boulanger B.R., Fogarty C., Tennenberg A., Wiesinger B., Oross M., Wu S.C., Fowler C., Morgan N., and Kahn J.B. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin. Ther. 25 (2003) 485-506
34. Zbinden R., Punter V., and von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrobial. Agents Chemother. 46 (2002) 871-874